Nooter K - Search Results

1

Impact of body-size measures on irinotecan clearance: alternative dosing recommendations.

Mathijssen RH, Verweij J, de Jonge MJ, Nooter K, Stoter G, Sparreboom A. Mathijssen RH, et al. Among authors: nooter k. J Clin Oncol. 2002 Jan 1;20(1):81-7. doi: 10.1200/JCO.2002.20.1.81. J Clin Oncol. 2002. PMID: 11773157

2

Structural identification and biological activity of 7-methyl-10,11-ethylenedioxy-20(S)-camptothecin, a photodegradant of lurtotecan.

Loos WJ, Verweij J, Kehrer DF, de Bruijn P, de Groot FM, Hamilton M, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Clin Cancer Res. 2002 Mar;8(3):856-62. Clin Cancer Res. 2002. PMID: 11895919

3

Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.

Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A. Gelderblom H, et al. Among authors: nooter k. Clin Cancer Res. 2002 Apr;8(4):1237-41. Clin Cancer Res. 2002. PMID: 11948138 Clinical Trial.

4

Randomized cross-over evaluation of body-surface area-based dosing versus flat-fixed dosing of paclitaxel.

Smorenburg CH, Sparreboom A, Bontenbal M, Stoter G, Nooter K, Verweij J. Smorenburg CH, et al. Among authors: nooter k. J Clin Oncol. 2003 Jan 15;21(2):197-202. doi: 10.1200/JCO.2003.01.058. J Clin Oncol. 2003. PMID: 12525510 Clinical Trial.

5

Red blood cells: a neglected compartment in topotecan pharmacokinetic analysis.

Loos WJ, Gelderblom H, Verweij J, van Boven-van Zomeren DM, Nooter K, Stoter G, Sparreboom A. Loos WJ, et al. Among authors: nooter k. Anticancer Drugs. 2003 Mar;14(3):227-32. doi: 10.1097/00001813-200303000-00006. Anticancer Drugs. 2003. PMID: 12634617 Clinical Trial.

6

Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

Loos WJ, de Jongh FE, Sparreboom A, de Wit R, van Boven-van Zomeren DM, Stoter G, Nooter K, Verweij J. Loos WJ, et al. Among authors: nooter k. J Clin Oncol. 2006 Apr 1;24(10):1499-506. doi: 10.1200/JCO.2005.03.0056. J Clin Oncol. 2006. PMID: 16574999 Clinical Trial.

7

Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection.

de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. de Bruijn P, et al. Among authors: nooter k. J Chromatogr B Biomed Sci Appl. 1997 Sep 26;698(1-2):277-85. doi: 10.1016/s0378-4347(97)00290-9. J Chromatogr B Biomed Sci Appl. 1997. PMID: 9367218 Free article.

8

Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces.

Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, Nooter K. Sparreboom A, et al. Among authors: nooter k. J Chromatogr B Biomed Sci Appl. 1998 Aug 7;712(1-2):225-35. doi: 10.1016/s0378-4347(98)00147-9. J Chromatogr B Biomed Sci Appl. 1998. PMID: 9698245 Clinical Trial.

9

Pharmacokinetics and bioavailability of oral 9-aminocamptothecin capsules in adult patients with solid tumors.

Sparreboom A, de Jonge MJ, Punt CJ, Nooter K, Loos WJ, Porro MG, Verweij J. Sparreboom A, et al. Among authors: nooter k. Clin Cancer Res. 1998 Aug;4(8):1915-9. Clin Cancer Res. 1998. PMID: 9717819 Clinical Trial.

10

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L. Sparreboom A, et al. Among authors: nooter k. Clin Cancer Res. 1998 Aug;4(8):1937-42. Clin Cancer Res. 1998. PMID: 9717822

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

150 results

Search Page

Filters